The participant may not enter the study if ANY of the following apply: 1. Pregnant or breast feeding, due to potential teratogenicity 2. Hepatic impairment – (AST or ALT > 3.5 x upper limit of normal) 3. Renal impairment – (eGFR <10ml/ minute) 4. Known history of retinopathy 5. Known history of G6PD deficiency 6. Known history of Myasthenia gravis 7. QT-prolongation (>430ms in males or >450ms in females, calculated as per investigators discretion) 8. Presently enrolled in an interventional drug study or on hydroxychloroquine or azithromycin for other therapeutic reasons 9. Unable to take medication via the oral or nasogastric route 10. Immunocompromised patients (see Appendix C) 11. Known sensitivity to Azithromycin (or other macrolide drugs), Hydroxychloroquine, zinc or Favipiravir NB See Section 9.1 for dose reduction guidance for patients with eGFR <50ml/ minute

The participant may not enter the study if ANY of the following apply: 1. Pregnant or breast feeding, due to potential teratogenicity 2. Hepatic impairment – (AST or ALT > 3.5 x upper limit of normal) 3. Renal impairment – (eGFR <10ml/ minute) 4. Known history of retinopathy 5. Known history of G6PD deficiency 6. Known history of Myasthenia gravis 7. QT-prolongation (>430ms in males or >450ms in females, calculated as per investigators discretion) 8. Presently enrolled in an interventional drug study or on hydroxychloroquine or azithromycin for other therapeutic reasons 9. Unable to take medication via the oral or nasogastric route 10. Immunocompromised patients (see Appendix C) 11. Known sensitivity to Azithromycin (or other macrolide drugs), Hydroxychloroquine, zinc or Favipiravir NB See Section 9.1 for dose reduction guidance for patients with eGFR <50ml/ minute